Skip to content
10-Q

Quarterly Report

PRELUDE THERAPEUTICS INC PRLD

0001193125-26-218173

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 79.65M sh
Shares Diluted Q1 2026 · Mar 31, 2026 82.52M sh
Shares Diluted Q1 2026 · Mar 31, 2025 75.99M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $47K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$21.69M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$34.23M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $21.76M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $35.26M
Stockholders Equity Q1 2026 · Mar 31, 2026 $60.18M
Stockholders Equity Q1 2026 · Dec 31, 2025 $68.64M
Stockholders Equity Q1 2026 · Mar 31, 2025 $103.18M
Stockholders Equity Q1 2026 · Dec 31, 2024 $131.46M
Current Liabilities Q1 2026 · Mar 31, 2026 $41.72M
Current Liabilities Q1 2026 · Dec 31, 2025 $52.99M
Total Liabilities Q1 2026 · Mar 31, 2026 $59.46M
Total Liabilities Q1 2026 · Dec 31, 2025 $72.68M
Current Assets Q1 2026 · Mar 31, 2026 $84.59M
Current Assets Q1 2026 · Dec 31, 2025 $105.69M
Total Assets Q1 2026 · Mar 31, 2026 $119.64M
Total Assets Q1 2026 · Dec 31, 2025 $141.32M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.13
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.42
Eps Basic Q1 2026 · Mar 31, 2026 −$0.13
Eps Basic Q1 2026 · Mar 31, 2025 −$0.42
Sga Expense Q1 2026 · Mar 31, 2026 $5.16M
Sga Expense Q1 2026 · Mar 31, 2025 $5.79M
Rd Expense Q1 2026 · Mar 31, 2026 $13.6M
Rd Expense Q1 2026 · Mar 31, 2025 $28.82M
Net Income Q1 2026 · Mar 31, 2026 −$10.39M
Net Income Q1 2026 · Mar 31, 2025 −$32.09M
Operating Income Q1 2026 · Mar 31, 2026 −$14.18M
Operating Income Q1 2026 · Mar 31, 2025 −$34.61M
Revenue Q1 2026 · Mar 31, 2026 $4.58M
Revenue Q1 2026 · Mar 31, 2025 $0